- Lobe Sciences (LOBE) released an update for its clinical development plans for its proprietary Psilocin-based compound L-130
- The company is approaching the development of global commercial markets with a disruptive approach to treating anxiety conditions with sequential sub-psychedelic dosing
- Initial Phase 1 clinical trials will utilize Clearway Global’s network of contract research organizations, and the first subject is expected to enter the first trial in December; topline data will be available for review early in Q1 2023
- Lobe Sciences Ltd. (LOBE) is up 10 per cent, trading at C$0.055 per share at 11:25 am ET
Lobe Sciences (LOBE) released an update for its clinical development plans for its proprietary Psilocin-based compound L-130.
The company’s Chief Executive Officer, Philip J. Young, commented that the team has received regulatory clearance to conduct its Phase 1 study, which is a combination of safety and pharmacokinetics evaluation of a fixed dose of L-130.
“It is important to remember that we are approaching the development of global commercial markets with a disruptive approach to treating anxiety conditions with sequential sub-psychedelic dosing of our compounds. Since the majority of patients with anxiety-related conditions are cared for by their personal family physician, our goal is to create a treatment regimen that is effective and easily prescribed by the patient’s personal physician.”
Lobe Sciences’ CSO, Maghsoud Dariani, added that it is important to remember that in just 12 months, the company had transformed into a fully integrated virtual drug development operation.
“We now have multiple New Chemical Entities (NCEs), including L-130, that are entering human trials. L-131 is entering pre-clinical trials as we prepare a pediatric Orphan Drug Application with the potential of receiving a Priority Review Voucher for L-131. All of this positions Lobe Sciences among the leaders in the small group of companies who are in clinical development of psychedelic drugs.”
The company has received regulatory clearance to import L-130, regulated as a Schedule 1 substance in the United States and most countries around the world.
Initial Phase 1 clinical trials will utilize Clearway Global’s network of contract research organizations. The first subject is expected to enter the first trial in December; topline data will be available for review early in Q1 2023.
A second Phase 1 trial is scheduled for Q1 2023 and will accurately assess the therapeutic window for the subsequent Phase 2a trial planned to follow.
Lobe Sciences (LOBE) is a Canadian biopharmaceutical company focused on discovering and developing psychedelic-derived medicines for neurologic and brain diseases.
Lobe Sciences Ltd. (LOBE) is up 10 per cent, trading at C$0.055 per share at 11:25 am ET.